688091.SH
Shanghai Yizhong Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 36.96
−7.65%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 39.25
From 52W high−23.18%
Volume1.99M
Market capCNY 7.64B
P/E (TTM)118.3x
P/S (TTM)25.4x
Div yield—
Key dataSep 18, 2026
Open
CNY 39.25
From 52W high
−23.18%
Volume
1.99M
Market cap
CNY 7.64B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
106.0x
P/E (TTM)
118.3x
RSI (14)
50.6
MomentumView details →
1D Return
−7.65%
YTD Return
—
Similar companies
Latest newsMore news →
Shanghai Yizhong announced its H1 2026 results: revenue of 166 million yuan, up 3.45% year-on-year; net profit attributable to shareholders of 42.3036 million yuan, up 11.31% year-on-year.26d agoShanghai Yizhong received approval from China's National Medical Products Administration for the clinical trial of its investigational drug YXC-002 for non-small cell lung cancer.33d agoShanghai Yizhong's wholly-owned subsidiary Shanghai Youxi Chuang Pharmaceutical Technology received a drug clinical trial approval notice from China's National Medical Products Administration for its self-developed innovative drug YXC-001 (a trifunctional antibody fusion protein) for the treatment of advanced solid tumors.34d ago